CoChat

Regression of Choroidal Neovascularization Results in Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Eyes

Open access
Channa, Roomasa, Sophie, Raafay, Bagheri, Saghar, Shah, Syed M., Wang, Jiangxia, Adeyemo, Olukemi, Sodhi, Akrit, Wenick, Adam, Ying, Howard S., Campochiaro, Peter A. · 2015 · American Journal of Ophthalmology
Cited by 54

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

PURPOSE: To determine the incidence and progression of macular atrophy in patients with neovascular age-related macular degeneration (AMD) treated with vascular endothelial growth factor (VEGF) antagonists. DESIGN: Retrospective interventional case series. METHODS: All patients with neovascular AMD treated by the same physician during a 12-month period of ascertainment had all images from their entire follow-up period evaluated, and areas of retina that developed atrophy were compared to the same areas prior to the onset of anti-VEGF treatment. Longitudinal measurements of retinal atrophy were made. RESULTS: In 39 patients, 52 eyes with neovascular AMD were identified. We excluded 5 eyes from analysis (4 had retinal pigment epithelium tears, and 1 had a laser scar). Fundus photographs of the remaining eyes showed that 18/47 eyes (38%) contained hypopigmented areas suggestive of atrophy within the macula at some time during follow-up. Spectral-domain optical coherence tomography confirmed that these areas had loss of retinal pigmented epithelium and ellipsoids zones, with or without subretinal material suggestive of subretinal fibrosis. Comparison of fundus photographs with fluorescein angiograms showed that in 13/18 eyes (72%), atrophy developed in areas previously occupied by choroidal neovascularization, and the other 5 eyes had atrophy prior to the onset of anti-VEGF treatment. The mean (±standard deviation) rate of increase in pure atrophic areas (no subretinal material) was 0.7 ± 0.8 mm2 per year, with a range of 0.01–2.6 mm2/year. CONCLUSION: Treatment of neovascular AMD with a VEGF-neutralizing protein can result in regression of choroidal neovascularization, which is sometimes associated with atrophy of overlying retina.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajo.2014.09.012

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 54

Metadata

Authors
Channa, R., Sophie, R., Bagheri, S., Shah, S. M., Wang, J., Adeyemo, O., Sodhi, A., Wenick, A., Ying, H. S., & Campochiaro, P. A.
Venue
American Journal of Ophthalmology
Publisher
Elsevier BV
Published
2015-01
Volume
159
Issue
1
Pages
9-19.e2
ISSN
0002-9394 (ISSN-L)
OpenAlex
W1987001896
Cited by
54
References
8
FWCI
6.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regression of Choroidal Neovascularization Results in Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Eyes. https://app.cochat.ai/papers/10.1016/j.ajo.2014.09.012
The paper
Channa, R., Sophie, R., Bagheri, S., Shah, S. M., Wang, J., Adeyemo, O., Sodhi, A., Wenick, A., Ying, H. S., & Campochiaro, P. A. (2015). Regression of Choroidal Neovascularization Results in Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Eyes. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2014.09.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.